A narrative review of metabolomics approaches in identifying biomarkers of doxorubicin-induced cardiotoxicity.

ABSTRACT:

Background

While anthracyclines, commonly used in cancer treatment, are well known to cause cardiotoxicity, no validated biomarkers currently exist that can predict the early development of doxorubicin-induced cardiotoxicity (DIC). Therefore, identifying early biomarkers of DIC is urgently needed. Metabolomics approaches have been used to elucidate this relationship and identified related metabolite markers. However, differences in pre-clinical model systems make it challenging to draw definitive conclusions from the discoveries and translate findings into clinical applications.

Aim of review

A systematic literature search on metabolomics studies of DIC was conducted with the goal to identify and compare study results reported using in vitro models, animal models, and studie

SUBMITTER: Singh A 

PROVIDER: S-EPMC12085340 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature